Lumexa Imaging (NasdaqGS:LMRI) FY Conference January 12, 2026 10:30 AM ET Company ParticipantsCaitlin Zulla - CEOTony Martin - CFOChristian Behrenbruch - CEOJason Coloma - CEOConference Call ParticipantsNone - AnalystAnupam Rama - Senior Biotech AnalystBen Rossi - Healthcare Facilities AnalystChris Cooper - Australian Healthcare AnalystBen RossiThank you all for joining us here in person. And for those joining us via webcast, my name is Ben Rossi, and I'm the Healthcare Facilities Analyst here at JPMorgan. ...

Lumexa Imaging (NasdaqGS:LMRI) FY Conference January 12, 2026 10:30 AM ET Company ParticipantsCaitlin Zulla - CEOTony Martin - CFOConference Call ParticipantsBen Rossi - Healthcare Facilities AnalystBen RossiThank you all for joining us here in person and for those joining us via webcast. My name is Ben Rossi, and I'm the Healthcare Facilities Analyst here at JPMorgan. We are excited to be welcoming Lumexa Imaging to the stage here this morning. With us here today are CEO Caitlin Zulla and CFO Tony Martin. ...

Company Overview - Lumexa Imaging is a national outpatient imaging platform with the 2nd largest outpatient imaging center footprint across 13 states[12] - The company provides advanced (MRI, CT, PET) and routine (X-ray, ultrasound, mammography) diagnostic imaging services[12] - As of December 31, 2025, Lumexa Imaging has established 44 de novo sites since its formation[12] Financial Performance (LTM 9/30/25) - Consolidated GAAP Revenue is $1,003 million[17] - Adjusted EBITDA is $220 million with a 22% margin[17] - System-wide revenue from advanced imaging accounts for 63% of the total[17] Market and Growth - The US diagnostic imaging services market was valued at $140 billion in 2024, with a CAGR of 5.9% from 2019[28] - Advanced imaging (MRI, CT) is driving market growth, with a revenue growth of 5.7% from 2019-2024, more than double the routine imaging growth of 2.6%[31] - Lumexa Imaging operates in attractive geographies with ~0.6% to ~1.4% population growth, approximately 2x the US average[38] Technology and AI - The company is leveraging an ecosystem of innovation with ongoing implementation of AI tools[63, 65] - Approximately 45% MRI Fast Scan implementation[67] - Approximately 10% of CPT coding automated[67] Health System Partnerships - Lumexa Imaging has 8 joint ventures across 86 centers[21] - The company takes 49% ownership of JV[86]

Core Insights - RadNet, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 10:30 a.m. PST [1][2] - The company is a leading provider of diagnostic imaging services in the U.S., operating a network of 407 outpatient imaging centers [2] Company Overview - RadNet, Inc. specializes in high-quality, cost-effective diagnostic imaging services and is recognized for its extensive network of imaging centers [2] - The company operates in several states, including Arizona, California, Delaware, Florida, Maryland, New Jersey, New York, and Texas [2] - RadNet employs over 11,000 team members, including radiologists, technologists, and support staff [2] Presentation Details - The presentation will take place at The Westin St. Francis Hotel in San Francisco, CA [2] - A live webcast of the presentation will be available for access and replay [2]

Core Insights - RadNet, Inc. has acquired Radiology Regional, expanding its presence in Southwest Florida with 13 new imaging centers [1][2][3] - The acquisition is expected to generate approximately $100 million in revenue for RadNet in 2026 [3] Company Overview - RadNet is a leading provider of outpatient diagnostic imaging services in the U.S., operating 407 imaging centers across various states [4] - Radiology Regional has been a significant player in the Southeast U.S. for over 50 years, offering a wide range of diagnostic services [5] Strategic Implications - The acquisition allows RadNet to leverage its operational efficiencies and advanced imaging technologies to meet the growing demand for imaging services in Florida [3] - The integration of AI-powered innovations from RadNet is expected to enhance clinical accuracy and improve patient experience at the newly acquired centers [3] Workforce Impact - The acquisition adds an estimated 400 employees and 44 contracted radiologists to RadNet's workforce [2]

Bench of veteran leaders elevated to drive RadNet’s continued growth and innovationLOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services and a premier global developer of digital health solutions, announced today the promotion of four senior leaders to expanded executive roles in recognition of their decades of operational excellence and strategic growth. Effective immediately, the execut ...

RadNet, Inc. (NASDAQ:RDNT) stock is trading lower on Tuesday. Hunterbrook Capital released a short report on Tuesday on the company, stating that the smaller companies are slapping "AI" on their pitch decks and watching their valuations soar.RadNet is a provider of freestanding, fixed-site diagnostic imaging services in the United States. It runs a network of 407 owned and/or operated outpatient imaging centers.Benzinga has reached out to RadNet for comments, and is yet to hear from the company.Short Seller ...

Lumexa Imaging, a chain of diagnostic imaging providers, filed for an IPO, disclosing growing revenue and shrinking losses https://t.co/WCpeN4EDnV ...

Core Insights - The largest real-world analysis of AI-driven breast cancer screening in the U.S. shows increased cancer detection rates and equitable benefits across diverse patient populations [1][3] Study Overview - The ASSURE study evaluated the AI-powered workflow in RadNet's Enhanced Breast Cancer Detection™ (EBCD™) program, analyzing mammograms from over 579,000 women across 109 imaging sites in multiple states [2] - The study compared traditional 3D mammography screening with an AI-driven protocol that integrates DeepHealth's FDA-cleared software and a Safeguard Review workflow [2] Results and Findings - The AI-powered workflow resulted in a 21.6% increase in cancer detection rates compared to standard 3D mammography, while maintaining recall rates within guidelines and improving positive predictive value by 15% [3] - For women with dense breasts, the AI workflow achieved a 22.7% increase in cancer detection rates, addressing both higher cancer risk and diagnostic challenges [3] - The study included over 150,000 Black women, highlighting the technology's potential to improve access to care for populations facing higher breast cancer mortality [3] Implementation and Impact - EBCD™ was launched nationwide in 2023, utilizing AI applications from DeepHealth's Breast Suite to enhance detection of difficult-to-find lesions [3] - The study's real-world findings emphasize the ability of AI to improve access to specialist-level care for women, regardless of their location [3] Company Background - RadNet, Inc. is the largest provider of outpatient diagnostic imaging services in the U.S., operating 407 imaging centers across several states [4] - DeepHealth, a subsidiary of RadNet, focuses on AI-powered health informatics to enhance clinical outcomes and operational efficiency in various health domains [5][6]

Core Insights - RadNet, Inc. has announced the acquisition of CIMAR UK to enhance its cloud-native healthcare image management solutions and integrate them with DeepHealth's AI-powered informatics [1][10][11] Group 1: Acquisition Details - The acquisition aims to advance connected imaging-based care by combining CIMAR's extensive image management infrastructure with DeepHealth's AI capabilities [2][3] - CIMAR's solutions are already deployed across over 50% of National Health Service Trusts and 80% of UK private hospital groups, indicating a strong market presence [2] - The integration is expected to create a richer solution for efficient and accessible imaging-based care across the UK [3] Group 2: Impact on Healthcare - The acquisition is positioned as a pivotal moment for CIMAR, allowing for a broader impact and improved access to intelligent imaging solutions [4] - DeepHealth's existing partnership with CIMAR supports NHS England's Lung Cancer Screening Program, which has shown early success in detecting lung cancers at more treatable stages [4][5] - The program has improved early detection rates from 29% historically to 76% for lung cancers detected through the screening initiative [4] Group 3: Future Aspirations - DeepHealth aims to scale digitally enabled care models across the UK and Europe, expanding the reach of connected healthcare models [5] - The combined capabilities of CIMAR and DeepHealth are expected to empower healthcare providers with advanced tools for medical imaging innovation [4][5]